Can I get a prescription from my pharmacist in NSW from 2027?

The expansion applies to over 250 specially trained pharmacists in a trial programme, not all NSW pharmacists. The 23 eligible conditions include COPD and hypertension, but the clinical specifics of what is prescribable (new initiations vs. resupply vs. dose adjustments) were not fully detailed in public announcements. If you have a chronic condition managed by a GP, it is worth asking your GP what the expansion means for your specific situation before making any changes to how you access care.

Why are GPs concerned about pharmacist prescribing?

The main GP and AMA argument is that conditions including high blood pressure and COPD can present with subtle features that mask more serious underlying diagnoses — a cough that appears to be COPD could be lung cancer; apparently stable hypertension could indicate secondary causes. GPs are trained specifically to detect these patterns across the full range of presentations. The concern is that a pharmacist with more limited training in differential diagnosis might miss an atypical presentation, and that fragmenting care across providers increases the risk of things falling through the gaps.

NSW pharmacists to prescribe for 23 chronic conditions from 2027

What just happened

NSW Premier Chris Minns has announced that over 250 specially-trained community pharmacists will be permitted to prescribe medications for 23 common chronic conditions — including COPD and hypertension — from early 2027, with all community pharmacists also allowed to administer National Immunisation Program vaccines from January 2027.

Medical Republic reported strong opposition from medical bodies. RACGP President Dr Michael Wright called for investment in general practice as the more evidence-supported path, citing recent critical reports from the Grattan and Sax Institutes on the pharmacy prescribing evidence base. AMA NSW President Dr Fred Betros went further, warning that pharmacists without full diagnostic training risk missing serious conditions — vomiting that masks appendicitis, cough that could be lung cancer rather than COPD.

The pharmacy guild’s position, by contrast, framed the expansion as a practical pressure valve. The guild argues the changes would free up 730,000 GP appointments annually — a number based on projecting from existing pilots including UTI treatment and oral contraceptive resupply, where over 2,000 women accessed pill resupply and 40,000 patients received UTI treatment through pharmacies since June without reported adverse events.

This is one of those policy stories where the headline — more healthcare access via pharmacists — sounds unambiguously good, but the implementation and the evidence base are more contested than the announcement suggests.

Both-and

The case for expanding pharmacist prescribing

The access argument is genuine. Australia has a real problem with GP availability. Bulk-billing rates have recovered, but wait times remain significant in many areas, particularly for non-urgent chronic disease reviews. Rural and regional communities face additional barriers. If a pharmacist can safely manage stable hypertension or issue a repeat inhaler prescription for documented COPD, those are appointments that could be freed up for more complex presentations that genuinely need GP-level assessment.

The pilots the guild cites are encouraging in their own terms: oral contraceptive resupply and uncomplicated UTI treatment in pharmacies are low-complexity, guideline-defined pathways where the clinical decision space is narrow. The evidence that these specific tasks can be performed safely by trained pharmacists is reasonably solid internationally.

Community pharmacists are also seeing patients daily. They notice adherence patterns, spot drug interactions, and sometimes identify deterioration before a scheduled GP review catches it. The question is not whether pharmacists are capable professionals — they are — but whether extending prescribing rights to chronic disease management represents a different category of task, with a different risk profile.

The case for caution

The medical profession’s concern is not primarily about pharmacist competence. It is about the nature of the conditions listed. The RACGP has consistently argued that conditions like COPD and hypertension sit within a diagnostic category where atypical presentations and comorbidities can change the clinical picture substantially. COPD exacerbations can be driven by new cardiac disease; hypertension in a 45-year-old woman might be primary or might flag renal disease or an endocrine cause that changes management entirely.

The Sax and Grattan Institute reports cited by RACGP President Dr Wright have scrutinised the international evidence on pharmacist prescribing in chronic disease and found it is thinner than the advocacy suggests, particularly for new initiations versus resupply of established medications. That distinction — resupply versus new prescription — matters enormously in the evidence assessment. Resupply of a stable, established prescription is clinically different from first-line prescribing, and the NSW expansion appears to include both.

There is also a care coordination concern. The more providers write prescriptions for the same patient, the more important it becomes that records are shared in real time. My Health Record and clinical messaging infrastructure in Australia are better than they were five years ago, but not seamless. Fragmentation of prescribing records is a real patient safety issue, not a rhetorical one.

2 cents

If you have a chronic condition managed by a GP — hypertension, COPD, diabetes — this expansion is worth understanding before January 2027. In NSW, certain prescriptions and vaccines will become available through community pharmacists as part of the trial. For straightforward resupply of stable medications with no recent changes, this could be convenient. For initial assessment, dose changes, or any situation where your condition has been less stable, the GP remains the right starting point.

The broader question — whether this model is good policy — will be answered by the trial data, which the NSW government has committed to collecting. The evidence debate is genuine, and the outcomes data will matter for future state-level decisions.

Verdict: maybe — a real access intervention with a contested evidence base. Worth watching as trial data emerges; not a reason to change how you currently manage stable chronic disease without talking to your GP first.